The multiple evidences provided for the efficacy of DOT1L inhibitors for both leukemia and solid tumors treatment were inducing a growth of interest in developing novel compounds with improved inhibitory potential and bioavailability (Figure 2). This evidence concerns the gene DOT1L and leukemia.